Can Retatrutide Be Compounded?
Short answer: No. Retatrutide cannot be legally compounded under current federal law. Compounding under both 503A (pharmacy) and 503B (outsourcing facility) frameworks requires an FDA-approved drug as the starting point or a drug on the FDA shortage list. Retatrutide has no approved NDA and is not on any shortage list. Any pharmacy or facility claiming to compound retatrutide is operating outside the law.
Quick Answers
What pharmacies carry retatrutide?
No pharmacy carries retatrutide. It is not FDA-approved and cannot be legally dispensed by any pharmacy — retail, specialty, compounding, or mail-order — as of September 2026. Any pharmacy claiming to dispense retatrutide is operating outside federal law and selling an unapproved, unverified substance.
The only legal source of retatrutide is an authorized clinical trial. See How to Find a Legitimate Retatrutide Clinical Trial for enrollment guidance.
Can a compounding pharmacy make retatrutide?
No. Compounding pharmacies — whether operating under 503A or 503B frameworks — cannot legally compound retatrutide. Retatrutide does not currently satisfy the federal requirements that would allow it to be used as a bulk drug substance for compounding: it has no approved NDA, is not on any FDA shortage list, and does not appear on the 503B bulk drug substance list. Any compounding pharmacy claiming to make retatrutide is violating federal law. Products sold as compounded retatrutide are unapproved new drugs subject to FDA enforcement.
This is different from semaglutide and tirzepatide, which were temporarily permitted to be compounded when placed on the FDA shortage list. Retatrutide has never been approved and has never been on a shortage list. See the full legal analysis below and the 503A pharmacies guide and 503B outsourcing guide.
Is compounded retatrutide legal?
No. Compounded retatrutide is not legal under current federal law. Retatrutide does not currently satisfy the federal requirements that would allow it to be used as a bulk drug substance for compounding under 503A or 503B. For 503A, it has no approved NDA and is not on the shortage list. For 503B, it is not on the FDA bulk drug substance list. Products sold as compounded retatrutide are unapproved new drugs subject to FDA enforcement action, including seizure and injunction.
The FDA has issued warning letters to vendors of unapproved GLP-1 compounds. For enforcement actions and safety risks: Online Retatrutide and Peptide Sellers and Fake and Illicit Retatrutide.
What is the retatrutide FDA approval status?
Retatrutide is investigational — not FDA-approved as of September 2026. Phase 3 TRIUMPH trials have reported positive topline results. Eli Lilly plans to submit a regulatory application to the FDA in Q1 2027. Standard FDA review takes 10–12 months from application acceptance. Approval is not guaranteed.
For the full regulatory timeline and pathway: FDA Regulatory Status and When Will Retatrutide Be Available?
Key Facts
What Federal Law Says About Compounding
Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), compounding pharmacies and outsourcing facilities may only compound drugs that meet specific legal criteria. For 503A pharmacies, the drug must be commercially available (or on a shortage list) and the compounding must be based on a valid patient-specific prescription. For 503B outsourcing facilities, the drug must appear on the FDA’s list of bulk drug substances.
Retatrutide meets none of these criteria. It has no approved NDA, is not commercially available, and is not on any FDA shortage list or bulk drug substance list. Retatrutide does not currently satisfy the federal requirements that would allow it to be used as a bulk drug substance for compounding under sections 503A or 503B.
503A vs 503B: What Each Framework Allows
| Framework | Who operates it | Compounding requirement | Retatrutide permitted? |
|---|---|---|---|
| 503A | State-licensed pharmacies | Drug must have an approved NDA or be on the FDA shortage list; requires a patient-specific prescription | No |
| 503B | FDA-registered outsourcing facilities | Bulk drug substance must appear on FDA's approved bulk drug substance list | No |
503A Pharmacies and Retatrutide
Under Section 503A of the FD&C Act, a licensed pharmacy may compound a drug for an individual patient if the drug is commercially available (or on the FDA shortage list) and a licensed prescriber has issued a valid patient-specific prescription. Retatrutide satisfies neither condition: it has no approved NDA and is not commercially available, and it does not appear on any FDA shortage list.
Retatrutide does not currently satisfy the federal requirements that would allow it to be used as a bulk drug substance for compounding under Section 503A. It has no approved NDA, is not commercially available, and does not appear on any FDA shortage list. A pharmacy claiming to compound retatrutide under this framework is violating federal law.
503B Outsourcing Facilities and Retatrutide
Section 503B outsourcing facilities may compound from bulk drug substances, but only those that appear on the FDA’s approved bulk drug substance list (the “503B bulks list”). This list is maintained by the FDA and updated periodically. Retatrutide does not appear on it.
Unlike 503A, 503B facilities do not require a patient-specific prescription, but they are subject to FDA inspection and must comply with Current Good Manufacturing Practice (CGMP) standards. None of this changes the fundamental requirement: the substance must be on the approved list. Retatrutide is not.
Why semaglutide and tirzepatide could be compounded (and retatrutide cannot)
Semaglutide and tirzepatide were placed on the FDA shortage list during documented supply shortages, which temporarily permitted compounding under both 503A and 503B frameworks. That permission was tied to the shortage designation — not to the drugs’ approval status alone. Retatrutide has never been approved and has never been on a shortage list. No shortage-based compounding permission exists or can exist for it.
FDA Enforcement Actions
The FDA has issued warning letters to vendors selling unapproved peptide compounds, including retatrutide analogs, labeled as research use only (RUO). The agency has reiterated that RUO designation does not authorize human use.
For more on the risks of purchasing from unregulated vendors, see Online Retatrutide and Peptide Sellers and What Is Research-Grade Retatrutide?
Source: FDA — Concerns About Unapproved GLP-1 Drugs Used for Weight Loss
The legal way to access retatrutide
Authorized clinical trials are the only legal pathway. Participants receive retatrutide at no cost under medical supervision at licensed research sites.
How to find a legitimate retatrutide clinical trial →Frequently Asked Questions
What pharmacies carry retatrutide?
No pharmacy carries retatrutide. It is not FDA-approved and cannot be legally dispensed by any pharmacy — retail, specialty, compounding, or mail-order — as of September 2026. Any pharmacy claiming to dispense retatrutide is operating outside federal law.
Can a compounding pharmacy make retatrutide?
No. Compounding pharmacies — whether operating under 503A or 503B frameworks — cannot legally compound retatrutide. Retatrutide does not currently satisfy the federal requirements that would allow it to be used as a bulk drug substance for compounding: it has no approved NDA, is not on any FDA shortage list, and does not appear on the 503B bulk drug substance list. Any compounding pharmacy claiming to make retatrutide is violating federal law.
Is compounded retatrutide legal?
No. Compounded retatrutide is not legal under current federal law. Retatrutide does not currently satisfy the federal requirements that would allow it to be used as a bulk drug substance for compounding under 503A or 503B. For 503A, it has no approved NDA and is not on the shortage list. For 503B, it is not on the FDA bulk drug substance list. Products sold as compounded retatrutide are unapproved new drugs subject to FDA enforcement.
What is the retatrutide FDA approval status?
Retatrutide is investigational — not FDA-approved as of September 2026. Phase 3 TRIUMPH trials have reported positive topline results. Eli Lilly plans to submit a regulatory application to the FDA in Q1 2027. Standard FDA review takes 10–12 months from application acceptance. Approval is not guaranteed.
What are the retatrutide prescription requirements?
There are no prescription requirements because retatrutide cannot be prescribed. It is not FDA-approved. After approval, prescription requirements will be determined by the FDA-approved labeling, which will specify the approved indications, dosing, and any Risk Evaluation and Mitigation Strategy (REMS) requirements.
Can a 503A pharmacy compound retatrutide?
No. According to the FDA, retatrutide cannot be used in compounding under current federal law. For 503A, retatrutide has no applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list. Any 503A pharmacy claiming to compound retatrutide is operating outside federal law.
Can a 503B outsourcing facility compound retatrutide?
No. According to the FDA, retatrutide does not appear on the 503B bulks list and is not being used to compound an FDA-approved drug appearing on the drug-shortage list. Products marketed as compounded retatrutide do not qualify for the applicable FD&C Act exemptions and are unapproved new drugs.
What about "research use only" (RUO) retatrutide from peptide vendors?
RUO retatrutide is not a legal compounded product — it is an unapproved drug sold under a research label. The FDA has made clear that the RUO designation does not exempt a product from the FD&C Act if it is marketed or intended for human use. Purchasing or using RUO retatrutide carries serious legal and health risks.
Why can semaglutide and tirzepatide be compounded but not retatrutide?
Semaglutide and tirzepatide were placed on the FDA shortage list during periods of supply shortage, which temporarily permitted compounding under 503A and 503B frameworks. Retatrutide has never been approved and has never been on a shortage list, so no such permission exists. It also does not meet the other eligibility criteria for either framework.
Will retatrutide ever be legally compoundable?
Possibly, but only under specific conditions: if it receives FDA approval AND is subsequently placed on the shortage list, or is added to the 503A or 503B bulks lists. None of these conditions are met as of September 2026. Even if approved, compounding would only be permitted during a documented shortage.
What is the legal way to access retatrutide?
The only legal way to access retatrutide in the United States is through an authorized clinical trial registered on ClinicalTrials.gov. Participants receive the drug at no cost under medical supervision.